1.Disseminated histoplasmosis presenting as fever and jaundice.
Eric W L WEE ; Seng Gee LIM ; Aileen WEE ; Louis Y A CHAI
Annals of the Academy of Medicine, Singapore 2009;38(8):739-740
Amphotericin B
;
therapeutic use
;
Antifungal Agents
;
therapeutic use
;
Fever
;
Histoplasma
;
Histoplasmosis
;
diagnosis
;
drug therapy
;
microbiology
;
pathology
;
Humans
;
Jaundice
;
Male
;
Middle Aged
2.Apolipoproteins and amyloid fibril formation in atherosclerosis.
Chai Lean TEOH ; Michael D W GRIFFIN ; Geoffrey J HOWLETT
Protein & Cell 2011;2(2):116-127
Amyloid fibrils arise from the aggregation of misfolded proteins into highly-ordered structures. The accumulation of these fibrils along with some non-fibrillar constituents within amyloid plaques is associated with the pathogenesis of several human degenerative diseases. A number of plasma apolipoproteins, including apolipoprotein (apo) A-I, apoA-II, apoC-II and apoE are implicated in amyloid formation or influence amyloid formation by other proteins. We review present knowledge of amyloid formation by apolipoproteins in disease, with particular focus on atherosclerosis. Further insights into the molecular mechanisms underlying their amyloidogenic propensity are obtained from in vitro studies which describe factors affecting apolipoprotein amyloid fibril formation and interactions. Additionally, we outline the evidence that amyloid fibril formation by apolipoproteins might play a role in the development and progression of atherosclerosis, and highlight possible molecular mechanisms that could contribute to the pathogenesis of this disease.
Amyloid
;
chemistry
;
metabolism
;
physiology
;
Apolipoproteins
;
metabolism
;
physiology
;
Atherosclerosis
;
metabolism
;
Humans
;
Molecular Chaperones
;
metabolism
;
physiology
;
Phospholipids
;
metabolism
;
physiology
3.Overview of clinical trials for nasopharyngeal carcinoma(in the English literature).
Chinese Journal of Cancer 2010;29(8):709-714
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Chemotherapy, Adjuvant
;
Clinical Trials as Topic
;
Disease-Free Survival
;
Dose Fractionation
;
Humans
;
Nasopharyngeal Neoplasms
;
drug therapy
;
pathology
;
radiotherapy
;
Neoplasm Staging
;
Radiotherapy, Intensity-Modulated
;
Randomized Controlled Trials as Topic
;
Survival Rate
4.Low incidence of cardiac complications from COVID-19 and its treatment among hospitalised patients in Singapore.
Tony Yi Wei LI ; Jinghao Nicholas NGIAM ; Nicholas W S CHEW ; Sai Meng THAM ; Zhen Yu LIM ; Shuyun CEN ; Shir Lynn LIM ; Robin CHERIAN ; Raymond C C WONG ; Ping CHAI ; Tiong Cheng YEO ; Paul Anantharajah TAMBYAH ; Amelia SANTOSA ; Gail Brenda CROSS ; Ching Hui SIA
Annals of the Academy of Medicine, Singapore 2021;50(6):490-493
7.Research progress of phage therapy in orthopedic implant-related infection.
Zulipikaer MAIMAITI ; Z LI ; C XU ; J FU ; L B HAO ; L LIU ; J Y CHEN ; W CHAI
Chinese Journal of Surgery 2023;62(1):83-87
The widespread application of implantable materials has brought about a corresponding increase in implant-related complications, with implant-associated infections being the most critical. Biofilms, which often form on these implants, can significantly impede the effectiveness of traditional antibiotic therapies. Therefore, strategies such as surgical removal of infected implants and prolonged antibiotic treatment have been acknowledged as effective measures to eradicate these infections. However,the challenges of antibiotic resistance and biofilm persistence often result in recurrent or hard-to-control infections, posing severe health threats to patients. Recent studies suggest that phages, a type of virus, can directly eliminate pathogenic bacteria and degrade biofilms. Furthermore, clinical trials have demonstrated promising therapeutic results with the combined use of phages and antibiotics. Consequently, this innovative therapy holds significant potential as an effective solution for managing implant-associated infections. This paper rigorously investigates and evaluates the potential value of phage therapy in addressing orthopedic implant-associated infections, based on a comprehensive review of relevant scientific literature.
8.Clinicopathological and molecular genetic characteristics of ELOC mutated renal cell carcinoma.
Z WEN ; W H ZHANG ; J Y LIANG ; J CHAI ; Y M WANG ; W N XU ; Z WANG ; L N FAN
Chinese Journal of Pathology 2023;52(12):1204-1209
Objective: To investigate the clinicopathological features, molecular genetic features, differential diagnosis and prognosis of ELOC mutated renal cell carcinoma. Methods: From January 2015 to June 2022, 11 cases of renal cell carcinoma with clear-cell morphology, expression of CAⅨ and CK7 and no 3p deletion were collected. Two cases of ELOC mutant renal cell carcinoma were diagnosed using whole exome sequencing (WES). The clinical features, morphology, immunophenotype, FISH and WES results were analyzed. The relevant literature was reviewed. Results: The two patients were both male, aged 29 and 51 years, respectively. They were both found to have a renal mass by physical examination. The maximum diameters of the tumors were 3.5 cm and 2.0 cm, respectively. At the low magnification, the tumors were well-defined. The tumor cells showed a pushing border and were separated by thick fibrous bands, forming nodules. The tumor cells were arranged in a variety of patterns, including tubular, papillary, solid nest or alveolar. At high magnification, the tumor cells were large, with well-defined cell borders and clear cytoplasm or fine eosinophilic granules. CAⅨ was diffusely box-like positive in both cases. Case 1 was partially and moderately positive for CK7, strongly positive for CD10, diffusely and moderately positive for P504S, and weakly positive for 34βE12. In case 2, CK7 and CD10 were both partially, moderately positive and P504s were diffusely positive, but 34βE12 was negative. FISH results showed that both cases had no 3p deletion. ELOC c.235T>A (p.Y79N) mutation was identified using WES in case 1, while ELOC c.236_237inv (p.Y79C) mutation was identified in case 2. Conclusions: As a new clinical entity, ELOC mutated renal cell carcinoma may be underdiagnosed due to its overlap with clear cell renal cell carcinoma in morphology and immunophenotype. The diagnosis of renal cell carcinoma with ELOC mutation should be confirmed by morphology, immunohistochemistry, FISH and gene mutation detection. However, more additional cases are needed to explain its biological behavior and prognosis.
Humans
;
Male
;
Biomarkers, Tumor/genetics*
;
Carcinoma, Renal Cell/pathology*
;
Chromosome Aberrations
;
Kidney Neoplasms/pathology*
;
Molecular Biology
;
Mutation
;
Prognosis